All In Biotech

Drug Trial Radar · NCT06270225

A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

A Randomized, Open-label, Active-Controlled Phase II Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.

Last checked: Nov 19, 2026Latest source record: Aug 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

157

Actual

Start

Mar 30, 2024

Primary completion

Oct 2024

Study completion Dec 2024

Sponsor

Sponsor type
Industry
First posted
Feb 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment.

Conditions

  • Gout Arthritis

Interventions

  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mgDrug

    Subjects will receive one s.c. injection of SSGJ-613 on Day 1.

  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mgDrug

    Subjects will receive one s.c. injection of SSGJ-613 on Day 1.

  • Colchicine 0.5 mgDrug

    Subjects will receive 0.5mg/d Colchicine for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of acute gout flaresTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Huashan Hospital Fudan University-Rheumatology

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.